Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Log In

    Show
    Forgot your password?
    Log In
    Or create a new account (it's free)

    Forgot Password?

    Enter your email address and we'll send you a link to reset your password.

    Get New Password

    Sign In Required

    To save favorites, you must log in.

    Creating an account is free, easy, and takes about 60 seconds.

    Attention COACH STUDY participants:

    The principal investigators of the study request that you use the official version of the modified score here.

    EUTOS Score for Chronic Myelogenous Leukemia (CML)

    Predicts outcomes after CML treatments, specifically adjusted for tyrosine kinase treatments.
    Favorite

    INSTRUCTIONS

    Use in newly-diagnosed patients before starting therapy.

    When to Use
    Pearls/Pitfalls
    Why Use

    Newly-diagnosed CML patients prior to discussions regarding prognosis and treatment options.

    • The EUTOS (European Treatment and Outcome Study) Score predicts survival and can also be used to predict the probability of complete cytogenetic response at 18 months.
    • Has better predictive value than the Sokal Score.
    • Spleen size estimation is subjective; however, that subjectivity is also included in other CML prognostic scores.
    • Developed in patients treated with imatinib, so outcomes may not apply with newer generation therapies.
    • Estimates response to therapy to, and survival on, the reference TKI (tyrosine kinase inhibitor) imatinib.
    • Only requires two values, which can be clinically detected prior to completing a bone marrow biopsy.
    cm
    %

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Management

    Though there is no broad consensus on management, a conservative strategy is to treat low-risk patients with imatinib and reserve newer-generation TKIs for high risk patients.

    Critical Actions

    Can only be applied to a newly-diagnosed patient before starting therapy.

    Content Contributors
    Reviewed By
    • Michael Mauro, MD
    About the Creator
    Dr. Joerg Hasford
    Are you Dr. Joerg Hasford?
    Content Contributors
    Reviewed By
    • Michael Mauro, MD